5 cells after 24 hours treatment (Fig. 2B, upper), suggesting that RN-5 is active in stabilizing

hA3G ABT-263 order independent of Vif. The mechanism remains unknown. As IMB-26 protected hA3G by binding to hA3G,8 it could be a clue for future study. RN-5 exhibited an hA3G protection effect in the HCV-infected Huh7.5 cells as well (Fig. 2C, upper), parallel with which was a reduction of HCV core protein to a level almost undetectable when RN-5 concentration was up to 1.1 μg/mL (Fig. 2C, upper). Fluorescent immunostaining was done in the RN-5-treated HCV(+) Huh7.5 cells to visualize the in situ change. As shown in Fig. 2D, RN-5 treatment increased the hA3G level (red), and accordingly decreased intracellular HCV core protein signal (green). The activity of RN-5 on HCV DNA Synthesis inhibitor replication was dose-dependent (Fig. 2E, lower). The EC50 of RN-5 on HCV was 0.34 μg/mL (or 0.69 μM; Fig. 2E, lower) and CC50 in the MTT assay was over 60 μg/mL (122 μM; Fig. 2E, upper), resulting in a therapeutic index of over 176. Anti-HIV compound IMB-26

(Fig. 2A, right) is another new hA3G stabilizer; it blocked the interaction between hA3G and Vif by way of a direct binding at hA3G and therefore protected hA3G from degradation.8 IMB-26 also increased intracellular hA3G in Huh7.5 cells (Fig. 2B, lower; Fig. 2C, lower) and accordingly inhibited HCV (Fig. 2C, lower; Fig. 2E). These results indicate that stabilization of host hA3G is an effective and a novel approach to suppress HCV replication. As a nucleic acid sequence homologous to that of Vif gene was not found in HCV in GenBank, the hA3G degradation mechanism in HCV infection remains to be clarified. To ensure the hA3G-mediated anti-HCV mechanism for the compounds (RN-5 and IMB-26), their activity on HCV viral enzymes was examined using the human GS4.3 cell line. The cell line was derived from the Huh7.0 cells transfected with HCV subgenomic replicons containing NS3,

NS4A, NS4B, NS5A, and NS5B genes.13 These nonstructural genes cover almost all of the HCV replication medchemexpress enzymes; inhibiting any one of the enzymes terminates the replicon amplification.13 As shown in Fig. 3A, neither RN-5 nor IMB-26 inhibited amplification of the HCV replicons, indicating that the compounds were not inhibitors for any of the HCV enzymes. In this assay, interferon-alpha (Intron A) was used as a positive control, although its mechanism is not clear. The compounds were further tested in our cell-free HCV protease assay (NS3-4A), in which RN-5 and IMB-26 showed almost no inhibitory effect on the protease, even when the compound concentration was above 100 μg/mL (Fig. 3B). BILN2061, a known NS3-4A protease inhibitor, served as a positive control in the experiment. The experiment was repeated over three times. Meanwhile, external hA3G with HA tag at the C-terminus was transfected into the GS4.3 cells. As shown in Fig.